ACIU reports positive preliminary Phase 1 data for Aci-19764
ACIU Ac immune says its NLRP3 inhibitor Aci-19764 shows positive preliminary Phase 1 findings, including reported safety/tolerability and confirmed CSF penetration, with full Phase 1/1B results expected in H1 2027.
ACIU Ac immune announces positive preliminary phase 1 data for nlrp3 inhibitor Aci-19764 Ac immune - full phase 1/1B results for Aci-19764 expected in h1 2027 - Aci-19764 safe and well tolerated with confirmed csf penetration in phase 1 - Based on pk data Therapeutic dose is expected to be ≤10mg once daily - No serious adverse events or treatment withdrawals reported for Aci-19764